HR Execs on the Move

Ash Stevens Inc

www.ashstevens.com

 
Founded in 1962, Ash Stevens is a premier contract research organization that provides low-volume, high-value Active Pharmaceutical Ingredients (APIs). We understand the industry needs and utilize our expertise in pharmaceutical regulatory affairs to
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

GeneDx

GeneDx is focused on delivering personalized, actionable insights that improve health outcomes. We sit at the intersection of diagnostics and data science, pairing decades of genomic expertise with an unmatched ability to interpret clinical data at scale. Our exome and genome testing is among the best in the industry. We expect that it will be even more advanced in the future with the help of Centrellis®, our innovative health information platform. Powered by millions of medical records, Centrellis® integrates digital tools with artificial intelligence to ingest and synthesize clinical and genomic data. As a result of our robust test menu, including our exome and genome testing, and the comprehensive insights generated by Centrellis®, we are developing a more complete understanding of complex disease than ever before. This translates to faster diagnosis, more effective treatment plans, and enhanced drug discovery. Our offerings help a whole spectrum of healthcare partners -- clinicians, researchers, health systems, pharmaceutical companies, and payors -- improve patient experiences and advance population health.

Jamaican Medical Cannabis Corporation

JMCC Group is the leading global provider of premium quality, sustainably grown, Jamaican medical cannabis products and related services to customers around the world, including licensed producers, medical researchers, product developers, manufacturers and distributors.

ViaCyte

ViaCyte is a privately held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. ViaCyte`s product candidates are based on directed differentiation of pluripotent stem cells into PEC-01 pancreatic islet progenitor cells, which are then implanted in durable and retrievable cell delivery devices. ViaCyte demonstrated that when effectively engrafted, PEC-01 cells can mature into glucose-responsive insulin producing cells in patients with type 1 diabetes. To accelerate and expand its efforts, ViaCyte has established collaborative partnerships with leading companies including CRISPR Therapeutics and W.L. Gore & Associates.

Travere Therapeutics

At Travere Therapeutics, our mission is to identify, develop and deliver life-changing therapies to people living with rare disease. #InRareForLife

Abgent

Abgent is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.